BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
- Conditions
- Hepatitis C Infection
- Interventions
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 74
- Registration Number
- NCT00874770
- Locations
- 🇺🇸
Alabama Liver & Digestive Specialists (Alds), Montgomery, Alabama, United States
🇺🇸Llc Dba The Research Institute, Springfield, Massachusetts, United States
🇺🇸Veterans Affairs Medical Center, Bronx, New York, United States
Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Drug: Combination of Bendamustine + Dasatinib
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00872976
- Locations
- 🇺🇸
Local Institution, Nashville, Tennessee, United States
Study of Immunotherapy to Treat Advanced Prostate Cancer
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 988
- Registration Number
- NCT00861614
- Locations
- 🇺🇸
Southern Cancer Center, Mobile, Alabama, United States
🇺🇸Arizona Clinical Research Center, Inc., Tucson, Arizona, United States
🇺🇸Loma Linda University Cancer Center, Loma Linda, California, United States
Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT00860275
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
First Line Hepato Cellular Carcinoma (HCC)
- Conditions
- Hepato Cellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1714
- Registration Number
- NCT00858871
- Locations
- 🇺🇸
Agajanian Institute Of Hematology And Oncology, Downey, California, United States
🇺🇸Sharp Clinical Oncology Research, San Diego, California, United States
🇺🇸James Graham Brown Cancer Center, Louisville, Kentucky, United States
Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT00859053
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2010-02-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT00855764
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 17
- Registration Number
- NCT00851045
- Locations
- 🇺🇸
Midwest Center For Hematology/Oncology, Joliet, Illinois, United States
🇺🇸Pharma Resource, East Providence, Rhode Island, United States
🇺🇸Compassionate Cancer Care Medical Group Inc, Fountain Valley, California, United States
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 255
- Registration Number
- NCT00850577
- Locations
- 🇺🇸
Palm Beach Cancer Institute, West Palm Beach, Florida, United States
🇺🇸Clintell, Inc., Skokie, Illinois, United States
🇺🇸North Canton Medical Clinic Center, Canton, Ohio, United States
An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism
- Conditions
- Atherosclerosis
- Interventions
- Procedure: Blood draw
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2009-11-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 150
- Registration Number
- NCT00847782
- Locations
- 🇨🇦
Local Institution, Montreal, Quebec, Canada